Stockreport

Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry [Yahoo! Finance]

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF In preclinical studies, VVD-214 was well tolerated and led to robust tumor regression in multiple models of MSI-high colorectal cancer Findings highlight the power of [Read more]